Articles

  • 1 week ago | wsj.com | Joseph Walker |Peter Loftus

    Your browser does not support HTML5 video. The Food and Drug Administration on Wednesday approved a powerful new prevention drug for HIV called Yeztugo that promises to keep most people virus-free with two shots a year. Made by Gilead Sciences, Yeztugo is the latest product approved in the lucrative market for HIV-prevention drugs, sometimes called pre-exposure prophylaxis, or PrEP, drugs. In clinical trials, 99.9% of participants receiving the drug didn’t acquire HIV, the virus that causes AIDS.

  • 3 weeks ago | jp.wsj.com | Jared S. Hopkins |Peter Loftus

    モデルナは第1次トランプ政権でコロナワクチンが称賛されたが、現在はワクチン規制の変更で逆風に直面 米バイオ医薬品会社モデルナは第1次トランプ政権における寵児(ちょうじ)だった。政府は同社による新型コロナウイルスワクチンの開発を全面的に支援し、開発されたワクチンは多くの人々をウイルスから守った。だが現在、ワクチン製造全体への逆風が強まり、モデルナは第2次トランプ政権の標的となっている。 米食品医薬品局(FDA)の動きはモデルナにとって新たな打撃となった。FDAは5月30日、モデルナの次世代コロナワクチンを承認した。ただ、接種対象は高齢者と健康上のリスクがある12~64歳に限定され、患者層は同社が意図していたよりも狭いものとなった。Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8ウォール・ストリート・ジャーナル日本版今すぐ購読する

  • 3 weeks ago | wsj.com | Jared S. Hopkins |Peter Loftus

    The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rulesIn the latest setback for Moderna, the Food and Drug Administration on Friday approved its next-generation Covid shot for a narrower population of patients than the company intended. The approval grants use of the vaccine only in older adults and people aged 12 to 64 with health risks. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved.

  • 3 weeks ago | livemint.com | Jared S. Hopkins |Peter Loftus

    Global Summary The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules. This is a Mint Premium article gifted to you. Subscribe to enjoy similar stories. The Trump administration is seeking to reshape the regulation, recommendations and development of vaccines.

  • 3 weeks ago | jp.wsj.com | Peter Loftus |Noemie Bisserbe

    デンマークの製薬大手ノボノルディスクは2023年、糖尿病治療薬「オゼンピック」と肥満症治療薬「ウゴービ」の需要急増を追い風に、時価総額でフランスの高級ブランドグループ、LVMHモエヘネシー・ルイヴィトンを抜き、欧州企業の首位に立った。 現在、同社は自ら切り開いた肥満症治療薬の市場で支配力を失っている。Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
20K
Tweets
5K
DMs Open
Yes
Peter Loftus
Peter Loftus @Loftus
28 Feb 24

RT @jenniferlevitz: “Not for the squeamish.” The Mütter Museum has been collecting human body parts for 160 years. A tumor its donor named…

Peter Loftus
Peter Loftus @Loftus
1 Apr 23

RT @aaronzitner: Friends of a free press: Please read and share our article about Evan Gershkovich of The Wall Street Journal, the distingu…

Peter Loftus
Peter Loftus @Loftus
31 Mar 23

Editors of more than three dozen news organizations signed a letter calling for the release of Wall Street Journal reporter Evan Gershkovich #IStandwithEvan https://t.co/TCAvLHzkIS via @WSJ